Company News

SILTISS and Inserm Sign Accord

Silab Group subsidiary has exclusive rights to use tissue engineering technology.

Author Image

By: Christine Esposito

Editor-in-Chief

SILTISS, the new subsidiary of the Silab Group founded in January 2016, has acquired exclusive rights to use a tissue engineering technology developed by Inserm. The exclusive accord was signed by Pascale Augé, chairman of the board of directors, Inserm Transfert, and Jean Paufique, chairman and founder of SILTISS, on April 19 in Brive.   SILTISS develops, produces and markets natural-origin biomaterials which promote or induce the tissue regeneration process. The initial applications relate t...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters